Hareth Nahi

The applicant has been a treating physician for the last 23 years for patients with myeloma, the median survival has increased from 3 to >10 years. The project is a direct consequence of the questions from everyday life with the patients. The key question in our research over the years has been and still is to identify why some patients have a quiescent disease with good long-term survival after standard treatment, while others have a more aggressive disease that does not respond to treatment and has a very dismal survival. Better understanding can be achieved through a better mapping of the biology of the disease and resistance mechanisms of the cancer cell in the individual patient. Multiple myeloma is the second most common blood cancer, despite advances in treatment, most patients suffer from relapse. We investigate new treatment methods that may be effective where conventional therapy fails, try to understand the mechanisms of action and identify the group of patients who would benefit most from the drug or treatment method with no or minimal side effects. We are establishing new prognostic markers predicting which patients will relapse and introducing new treatments. Our research has direct clinical implications both for prognosis and choice of treatment. Our optimal goal is a cure, which is achievable in the near future, through the introduction of new treatments/combinations. We also aim to better understand action/resistance mechanisms and correlate them with cancer cells' DNA changes, which can differ from patient to patient, even within the same disease. New markers of relapse aimed at

on the one hand shortening the treatment time thus fewer side effects if negative and on the other hand changing/extending the treatment in those with positive markers for a better survival.

Multiple myeloma (MM) is an incurable malignant disease. This disease accounts for about 2% of all cancer deaths and almost 20% of deaths caused by hematological malignancies. New drugs have improved the prospects for long-term survival, despite this improvement in survival in recent years, relapses affect almost all patients. Thus, new treatment modalities are needed for patients with MM. In recent years, immune and cellular therapies have rapidly evolved as exciting new cell-based therapies for many cancers, including MM. One mystery that remains to be solved is the serious side effects associated with such therapy. The purpose is to identify prognostic parameters, in particular genes on specific chromosomes, as well as perform a thorough analysis when the disease recurs and reduce side effects of immunotherapy. Specifically, we will A- Analyze prognostic parameters related to specific therapies and differences in outcomes B- Improving current immune / cell therapies in terms of effectiveness and reducing side effects C- Analyze the genetic characterization of MM at diagnosis and progressive disease, partly to better predict the prognosis, partly to provide any possible future therapies that target specific genes in recurrence The key issue in our research over the years has been and still is to identify why some patients with multiple myeloma have good long-term survival after standard treatment, while others have a more aggressive disease. Our hypothesis is that the right combination of available treatment methods and the addition of new therapies improves the results. We investigate new treatment methods that can have an effect where ordinary treatment fails, try to understand the mechanisms of action. Our goal is to achieve a cure in patients with myeloma and in cases where a cure cannot be achieved. We hope to achieve a significant extension of survival.

Multiple myeloma (MM) is an incurable malignant disease. This disease accounts for about 2% of all cancer deaths and almost 20% of deaths caused by hematological malignancies. New drugs have improved the prospects for long-term survival, despite this improvement in survival in recent years, relapses affect almost all patients. Thus, new treatment modalities are needed for patients with MM. In recent years, immune and cellular therapies have rapidly evolved as exciting new cell-based therapies for many cancers, including MM. One mystery that remains to be solved is the serious side effects associated with such therapy. The purpose is to identify prognostic parameters, in particular genes on specific chromosomes, as well as perform a thorough analysis when the disease recurs and reduce side effects of immunotherapy. Specifically, we will A- Analyze prognostic parameters related to specific therapies and differences in outcomes B- Improving current immune / cell therapies in terms of effectiveness and reducing side effects C- Analyze the genetic characterization of MM at diagnosis and progressive disease, partly to better predict the prognosis, partly to provide any possible future therapies that target specific genes in recurrence The key issue in our research over the years has been and still is to identify why some patients with multiple myeloma have good long-term survival after standard treatment, while others have a more aggressive disease. Our hypothesis is that the right combination of available treatment methods and the addition of new therapies improves the results. We investigate new treatment methods that can have an effect where ordinary treatment fails, try to understand the mechanisms of action. Our goal is to achieve a cure in patients with myeloma and in cases where a cure cannot be achieved. We hope to achieve a significant extension of survival.

Multiple myeloma (MM) is an incurable malignant tumor that accounts for about 2% of all cancer deaths and almost 20% of deaths caused by hematological malignancies. The presence of different chromosomal abnormalities among the malignant cells has been shown to have an effect on prognosis. Better understanding and classification of prognostic factors is needed to understand why different patients respond differently to treatment. By methodically analyzing both biological and clinical effects of different treatment strategists, we hope for better individual choice of treatment and the like. this better response in the individual. Analyze prognostic parameters, especially chromosome aberrations and genes on specific chromosomes. Specifically, we will: A-perform a retrospective analysis of forecasting parameters. B-identify and isolate specific genes in the chromosome region part (8) (p21) and to analyze their trivial importance for the development of MM. C-Implement a systematic effort to identify loci and avenues. D-Explore resistance and mechanism of action of different treatment strategists MM is still incurable. A better understanding of the effects of cytogenetic abnormalities and specific genes located in aberrant regions can help to understand pathogenetic mechanisms which, in turn, can contribute to the design of new and more effective drugs. Systematic work to identify genes that are associated with an increased risk of developing MM. The identification of such genes can lead to the development of tools to identify individuals-at-risk, and, in the longer term, to the development of new treatments. Together these methods can improve results and be a step towards the goal of curing MM.

Multiple myeloma (MM) is an incurable malignant tumor that accounts for about 2% of all cancer deaths and almost 20% of deaths caused by hematological malignancies. The presence of different chromosomal abnormalities among the malignant cells has been shown to have an effect on prognosis. Better understanding and classification of prognostic factors is needed to understand why different patients respond differently to treatment. By methodically analyzing both biological and clinical effects of different treatment strategists, we hope for better individual choice of treatment and the like. this better response in the individual. Analyze prognostic parameters, especially chromosome aberrations and genes on specific chromosomes. Specifically, we will: A-perform a retrospective analysis of forecasting parameters. B-identify and isolate specific genes in the chromosome region part (8) (p21) and to analyze their trivial importance for the development of MM. C-Implement a systematic effort to identify loci and avenues. D-Explore resistance and mechanism of action of different treatment strategists MM is still incurable. A better understanding of the effects of cytogenetic abnormalities and specific genes located in aberrant regions can help to understand pathogenetic mechanisms which, in turn, can contribute to the design of new and more effective drugs. Systematic work to identify genes that are associated with an increased risk of developing MM. The identification of such genes can lead to the development of tools to identify individuals-at-risk, and, in the longer term, to the development of new treatments. Together these methods can improve results and be a step towards the goal of curing MM.

Multiple myeloma (MM) is an incurable malignant tumor that accounts for about 2% of all cancer deaths and almost 20% of deaths caused by hematological malignancies. The presence of different chromosomal abnormalities among the malignant cells has been shown to have an effect on prognosis. Better understanding and classification of prognostic factors is needed to understand why different patients respond differently to treatment. By methodically analyzing both biological and clinical effects of different treatment strategists, we hope for better individual choice of treatment and the like. this better response in the individual. Analyze prognostic parameters, especially chromosome aberrations and genes on specific chromosomes. Specifically, we will: A-perform a retrospective analysis of forecasting parameters. B-identify and isolate specific genes in the chromosome region part (8) (p21) and to analyze their trivial importance for the development of MM. C-Implement a systematic effort to identify loci and avenues. D-Explore resistance and mechanism of action of different treatment strategists MM is still incurable. A better understanding of the effects of cytogenetic abnormalities and specific genes located in aberrant regions can help to understand pathogenetic mechanisms which, in turn, can contribute to the design of new and more effective drugs. Systematic work to identify genes that are associated with an increased risk of developing MM. The identification of such genes can lead to the development of tools to identify individuals-at-risk, and, in the longer term, to the development of new treatments. Together these methods can improve results and be a step towards the goal of curing MM.

Multiple myeloma (MM) is an incurable malignant tumor that accounts for about 2% of all cancer deaths and almost 20% of deaths caused by hematological malignancies. The presence of different chromosomal abnormalities among the malignant cells has been shown to have an effect on prognosis. Better understanding and classification of prognostic factors is needed to understand why different patients respond differently to treatment. The prevalence varies in MM globally from 1 per 100,000 in China, to about 10 per 100,000 in Africa and African Americans. Development of MM is preceded by gamma globulinopathy of unknown importance (MGUS), M protein without other signs of MM. Analyze prognostic parameters, especially chromosome aberrations and genes on specific chromosomes. Specifically, we will: A-perform a retrospective analysis of prognostic parameters, especially chromosome abnormalities, related to specific treatments in patients with MM. B-identify and isolate specific genes in the chromosome region part (8) (p21) and to analyze their trivial importance for the development of MM. C-Implement a systematic effort to identify loci and alleles (specific sites on a chromosome) risks associated with an increased risk of developing MM, both in unselected cases and in high-risk families-siblings / children with MM Myeloma is still incurable cancer. A better understanding of the effects of cytogenetic abnormalities and specific genes located in aberrant regions can help to understand pathogenetic mechanisms which, in turn, can contribute to the design of new and more effective drugs. Systematic work to identify genes that are associated with an increased risk of developing MM. The identification of such genes can lead to the development of tools to identify individuals-at-risk, and, in the longer term, to the development of new treatments. Together these methods can improve results and be a step towards the goal of curing MM.

Multiple myeloma (MM) is an incurable malignant tumor that accounts for about 2% of all cancer deaths and almost 20% of deaths caused by hematological malignancies. The presence of different chromosomal abnormalities among the malignant cells has been shown to have an effect on prognosis. Better understanding and classification of prognostic factors is needed to understand why different patients respond differently to treatment. The prevalence varies in MM globally from 1 per 100,000 in China, to about 10 per 100,000 in Africa and African Americans. Development of MM is preceded by gamma globulinopathy of unknown importance (MGUS), M protein without other signs of MM. Analyze prognostic parameters, especially chromosome aberrations and genes on specific chromosomes. Specifically, we will: A-perform a retrospective analysis of prognostic parameters, especially chromosome abnormalities, related to specific treatments in patients with MM. B-identify and isolate specific genes in the chromosome region part (8) (p21) and to analyze their trivial importance for the development of MM. C-Implement a systematic effort to identify loci and alleles (specific sites on a chromosome) risks associated with an increased risk of developing MM, both in unselected cases and in high-risk families-siblings / children with MM Myeloma is still incurable cancer. A better understanding of the effects of cytogenetic abnormalities and specific genes located in aberrant regions can help to understand pathogenetic mechanisms which, in turn, can contribute to the design of new and more effective drugs. Systematic work to identify genes that are associated with an increased risk of developing MM. The identification of such genes can lead to the development of tools to identify individuals-at-risk, and, in the longer term, to the development of new treatments. Together these methods can improve results and be a step towards the goal of curing MM.